Thursday, 13 July 2023
by Rose White
Pharmaceutical company AFT Pharmaceuticals (ASX:AFP) has launched into online stores on Amazon in the U.S and Australia.
The company says the new AFT branded stories on the North American-facing and the Australian facing sites compliment and build upon its global e-commerce strategy.
AFT has been engaging with a specialist Amazon agency Sell Global, to launch on Amazon in the U.S and Australia.
“Building our online presence is a further element of our strategy to extend AFT’s reach around the world”
The company says the project has included researching the market opportunity, understanding the compliance requirements for imports, setting up quality product listings and brand presence, alongside advertising and promoting on the site.
Commenting on the launch, AFT Pharmaceuticals Founder and Managing Director Hartley Atkinson said: “Building our online presence is a further element of our strategy to extend AFT’s reach around the world.
It builds on the strong growth we are seeing in the Australiasian business, which is being fueled by growth from existing products and a planned 69 new product launches through until the end of FY26.”
Amazon’s site in the U.S and Australia will carry AFT’s trusted portfolio of Liposomal vitamins. The products made available for U.S, Canadian, and Australian customers will include the Vitamin C LipoSachet, Vitamin C LipoSachet for kids, Vitamin D LipoSachet, and Ferro LipoSachet.
Further launches of other products are planned for the Australian store in the coming months and the North American site after the initial launch is completed.
AFT has also expanded its operational hubs in Singapore and Malaysia to include Hong Kong and the United Kingdom. This will allow AFT to add selected products from its new and existing Australasian pipeline to these markets.
AFT Pharmaceuticals is an ASX-listed company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories that are distributed across ‘major’ pharmaceutical channels.